Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Michelle Kim

Cornea and External Diseases Specialist Durham, NC Medical Doctor

NPI 1144664590 CMS profile 5144651

2351 Erwin Rd, Durham, NC 27705

Open in the dashboard

General payments

$424

6 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Michelle Kim of Durham, NC is reported in the CMS Open Payments database as having received $424 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 16th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $84 1
2022 General $163 2
2021 General $159 2
2020 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Kim
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to Michelle Kim were reported at $0. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year Michelle Kim Cornea and External Diseases Specialist median Middle half National median
2019 $0 $276 $111–$734 $163
2020 $17 $146 $48–$330 $114
2021 $159 $254 $116–$566 $132
2022 $163 $251 $106–$729 $149
2023 $84 $344 $149–$759 $160
2024 $0 $366 $170–$927 $164
2025 $0 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. Alcon Vision LLC $200 3 payments
  2. Regeneron Healthcare Solutions, Inc. $122 1 payment
  3. Bausch & Lomb Americas Inc. $84 1 payment
  4. Carl Zeiss Meditec, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $407 5 payments
  2. Gift $17 1 payment
Products named General payments · program years 2020–2023
  1. Clareon $125 1 payment
  2. EYLEA $122 1 payment
  3. enVista MX60 IOL $84 1 payment
  4. AMVISC $84 1 payment
  5. Centurion $38 1 payment
  6. AcrySof IQ VIVITY IOL $37 1 payment
  7. None Specified $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,722

Median for Ophthalmology: 891

Drug cost

$50,621

Median for Ophthalmology: $68,233

Branded share of claims

9.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 517 $19,634
Cyclosporine Generic 95 $11,462
Latanoprost Generic 483 $5,684
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 146 $3,138
Brimonidine Tartrate Generic 105 $2,434
Timolol Maleate Generic 188 $2,351
Bimatoprost Generic 15 $1,644
Fluorometholone Generic 11 $1,060
Ofloxacin Generic 68 $994
Levobunolol Hcl Generic 34 $956

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$3,580

Medicare's payments for the services billed

Medicare patients

18

Average age 70

Services billed

26

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 0%
Atrial fibrillation 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record